Real World Evidence Insights

EAU 2025 presents a significant study on FGFR alterations in intermediate-risk non-muscle invasive bladder cancer (NMIBC). Dr. Morgan Rouprt highlighted a real-world analysis, revealing that 75% of intermediate-risk NMIBC patients possess FGFR alterations, based on the IBCG guidelines. Such a high prevalence suggests potential benefits from FGFR inhibitors like the TAR-210 system.

The study employed the BRIDGE Clinical Routine Register, examining 719 NMIBC samples, with 24% classified as intermediate-risk by IBCG criteria. These findings underscore the relevance of FGFR-focused therapies, offering a clear pathway to targeted treatment for this patient group. This research sheds light on the critical epithelial landscape of bladder cancer, driving innovative therapeutic approaches.

Dexter, established in 2022, is at the forefront of utilising Real World Evidence (RWE) through its innovative software products. DexterRWE automates data cleaning and extraction, revolutionising how observational studies identify associations like smoking with lung cancer. Already pivotal in over 130 studies, its power lies in unearthing inequalities in healthcare and redistributing resources effectively. Dexter plans to further broaden its scope to other big data sets, encompassing crime and mental health, demonstrating a promising future for digital health analytics.

Complementing DexterRWE, DexterCare revolutionises clinical audits by automating processes, significantly improving efficiency in healthcare settings like the NHS. DexterCare alleviates lengthy data collection further, supporting swift quality improvements. With its federated software ensuring patient confidentiality, Dexter paves the way for strategic partnerships and innovations, including automating clinical trial processes. By simplifying complex tasks, Dexter stands as a beacon of innovation, hinting at the transformative potential of technology in healthcare.

The 2nd IMPACCT Real World Evidence Summit 2025 is a pivotal forum for strategic innovation, gathering over 50 pharma RWE decision makers in Europe. This assembly delves into the intricacies of integrated evidence plans and study credibility, focusing on aligning statistical methodologies with regulatory frameworks. Esteemed speakers such as Lill-Brith Wium von Arx and Elena Panitti will lead discussions on advanced data sharing strategies and infrastructure optimisation, ensuring the dialogue resonates with professionals at the forefront of the field.

Participants will gain insights into elevating data quality and leveraging clinical research and HEOR expertise for comprehensive analysis. Engaging panels will tackle collaborations with DARWIN and refining patient-reported outcomes to accurately enhance treatment effectiveness in real-world contexts. The summit offers more than six hours dedicated to networking, fostering collaboration, and strategic insight exchange. A crucial event for those aiming to push the boundaries of integrated evidence and technological advancement in healthcare strategies.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) highlights the importance of real-world evidence (RWE) in shaping healthcare decisions. This aligns with a broader vision known as "Harnessing RWE to transform Healthcare Decision-Making in Europe," advocating for RWE to complement clinical trial data. RWE provides a comprehensive understanding of treatment outcomes, effectiveness, and safety within real-world settings, enriching the landscape of innovative medicine discovery and application.

RWE is likened to a 'magical dice,' offering diverse, valuable insights from everyday clinical practice that can significantly enhance healthcare strategies. By understanding how medicines perform in diverse populations, EFPIA argues for the integration of RWE into healthcare systems, promising a holistic approach that merges scientific rigour with real-world applicability. With moderate analytical depth, this concept invites curiosity and anticipation for its potential role in revolutionising healthcare decisions across Europe.